AHCCcapsules
Phase 2Small molecule
AHCCcapsules is one of 13 small molecule programs targeting HNSCC. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
18 competitors in HNSCC
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Keytruda
Merck & Co.Phase 2
Vectibix
AmgenPhase 1
Methylthioninium Chloride
PProvepharm SAS
Phase 1
SG001
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 2
Beyfortus
BeiGenePreclinical
JMT101
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
SYS6002
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
Gilotrif
Boehringer IngelheimPreclinical
AHCCcapsules
SShandong University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AHCCcapsules. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShandong University